H2O Innovation has a 132 per cent upside, Beacon Securities says

Water treatment tech company H2O Innovation’s (H2O Innovation Stock Quote, Chart TSXV:HEO) new acquisition in Texas gets the thumbs up from analyst Gabriel Leung of Beacon Securities, who in a research update on Monday raised his target price from $2.00 to $2.25.

Last week, Quebec City-based H2O closed on the previously announced acquisition of water and wastewater asset management company Hays Utility South Corporation, an $8.9 million all-cash deal that the company is funding through a private placement of 15.7 million shares (~39 per cent dilution) at $0.83 per share, representing gross proceeds of $13.1 million.

Leung says the deal makes sense for a number of reasons.

“First, it bulks up HEO’s presence in Texas, which is one of the fastest growing markets for water related infrastructure in North America,” says the analyst. “Second, the inclusion of Hays adds to HEO’s recurring revenue base, which we now estimate at just under 70 per cent of total revenues, helping to provide excellent earnings visibility (at a very attractive acquisition price).”

“Third, the additional EBITDA and private placement financing helps to reduce HEO’s leverage ratios to very manageable levels. And lastly, this acquisition helps to create more synergies and cross-selling opportunities between the company’s business lines,” he says.

Leung estimates that post-transaction, H2O will have about $5 million in cash against $19.5 million in debt. He is now calling for revenues of $99.7 million, $115.5 million and $130.2 million for fiscal years 2018, 2019 and 2020, respectively, and Adjusted EBITDA of $3.9 million, $7.2 million and $9.8 million in 2018, 2019 and 2020, respectively.

The analyst gives HEO a “Buy” rating, with the $2.25 target coming from a 14x FY20e EV/EBITDA estimate and representing a projected return of 132 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: heo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago